.jpg)
COVID-19 therapeutics. What have we learned from laboratory-based studies?
Andrew Owen
University of Liverpool, Liverpool, UK
Andrew Owen is co-director of the Centre of Excellence in Long-acting Therapeutics (CELT) and a professor of Pharmacology at the University of Liverpool. He is a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales.
His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of novel drug delivery technologies. Since March 2020, professor Owen has been intensively engaged in preclinical and clinical evaluation of SARS-CoV-2 antiviral candidates, and he sits on the Trial Management Group for AGILE, a seamless phase I/IIa COVID19 platform (www.agiletrial.net). He is co-inventor of patents relating to drug delivery and is principle investigator for LONGEVITY which is an international project that aims to translate novel long-acting medicines for malaria chemoprophylaxis, tuberculosis prevention and Hepatitis C Virus therapy. He also leads a modelling core for the NIH-funded Long-acting/Extended release Antiretroviral resource Program (www.LEAPresources.org). Professor Owen is a director and the CSO for Tandem Nano Ltd.